Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.
Artizan Biosciences has raised $1.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2025.
Artizan Biosciences's investors include Hatteras Venture Partners, Connecticut Innovations, Brii Biosciences, OUP (Osage University Partners), Biohaven Pharmaceutical.
Artizan Biosciences is headquartered in New York, United States.
Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.
Artizan Biosciences is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Artizan Biosciences — Funding & Investors." VCBacked, November 12, 2025, https://www.vcbacked.co/company/artizan-biosciences. Accessed July 21, 2026.
VCBacked. (2025). Artizan Biosciences — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/artizan-biosciences
{{cite web |title=Artizan Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/artizan-biosciences |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated